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Prostaglandin E2 amplifies epidermal growth factor-induced phosphorylation 





The signalling pathways of G-protein coupled receptors (GPCRs) and epidermal growth factor 
receptors (EGFRs) have been shown to communicate in mitogenic processes in many cells. 
Several mechanisms have been suggested to explain this; in particular transactivation is a 
mechanism that seems to be involved in many cases where signalling pathways intermingle. We 
have observed that prostaglandin E2 (PGE2) and other GPCR ligands enhance the mitogenic 
effect of epidermal growth factor (EGF) on hepatocytes. In this study we suggest that cross-talk 
between the pathways activated by these two agonists is not dependent on transactivation but a 
result of altered gene transcription caused by stimulation with PGE2. Our results indicate that 
transcription is altered so as to induce proteins that prolongate signalling in the EGFR pathway. 
These proteins inhibit the deactivation of the extracellular-regulated kinase (ERK), which is an 





Multicellular organisms depend on keeping a proper balance between the proliferation, growth 
and death of their cells. In order to keep this balance the cells need to communicate with each 
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other. Messages from one cell to another are mediated by molecules (mostly proteins) they 
secrete or have bound to their surface. Some of these molecules are growth factors and mitogens 
that induce growth and proliferation, others are survival factors that suppress apoptosis. All cells 
need to pass certain check points in their cell cycle in order to proliferate, and without the 
“permission” of a signal from a growth factor most cells are unable to get beyond these check 
points. When the balance between these growth regulating signals is disturbed the result may be 
excessive proliferation or a shortage of cell death, and in the end lead to proliferative disorders 
such as cancer. 
 
In this study we focus on the effect of a certain growth factor – the epidermal growth factor 
(EGF) – and its interaction with a prostaglandin (PGE2) which is known to enhance proliferation 
in many cells. We have observed that PGE2 enhances the proliferative effect of EGF in 
hepatocytes, and in this study we suggest that PGE2 does so by altering gene transcription and 
thereby modulating components in the intracellular pathway activated by EGF. 
 
 
The EGF receptor 
 
EGF mediates its signal by binding to the epidermal growth factor receptor (EGFR) on the cell 
surface. The EGFR is a membrane bound receptor, and one of its main functions is the regulation 
of cellular proliferation. Based on receptor affinity and structure the EGFR and three other 
receptors form a subfamily known as the ErbB receptor family (Holbro and Hynes, 2004). This 
subfamily belongs to the larger superfamily of receptor tyrosine kinases (RTKs) which all have 
certain qualities in common: They have a single transmembrane segment, and their intracellular 
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part contains a kinase domain that specifically phosphorylates tyrosine residues in other proteins. 
The intracellular kinase domain is activated upon binding of ligands (such as EGF) to the 
extracellular part of the receptor (Alberts et al., 2002). 
 
The EGFR is strongly involved in the control of cellular proliferation. This is suggested not only 
by in vitro experiments, but by the fact that many epithelial cancers are known to overexpress the 
EGFR or its ligands, or to contain mutated variants of the receptor (Jorissen et al., 2003). It has 
been difficult to pin down the physiological role of the EGFR because rodents with null 
mutations in the ErbB signalling system have died in utero or barely survived a few weeks after 
birth. In EGFR-null mice the organs particularly affected are skin, liver, gastrointestinal tract, 
lungs and brain (Jorisson et al., 2003; Holbro and Hynes, 2004). These findings confirm previous 
studies that have described EGFR as a regulator of proliferation. 
 
 
Activation of the EGFR 
 
Six ligands have been described for the EGFR. The epidermal growth factor (EGF) and the 
transforming growth factor alpha (TGFα) are the ones that have been most extensively studied; in 
addition amphiregulin, betacellulin, heparin-binding EGF and epiregulin may also activate the 
receptor (Holbro and Hynes, 2004). Without ligand stimulation there is an equilibrium of dimers 
and monomers of EGFR molecules in the surface of the cell (Jorissen et al., 2003). The dimers 
can be either homodimers or heterodimers, i.e. they may contain either two identical or two 
different members of the ErbB subfamily. The binding of a ligand to the ectodomain of such a 
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dimer causes a conformational change in the intracellular part of the receptor. This reorganisation 
brings the katalytic tyrosine kinase domains on each of the two receptor molecules into a position 
where they can phosphorylate and activate each other and also (auto- and trans-) phosporylate 
tyrosine residues on the non-katalytic parts of the two receptor molecules (Jorissen et al, 2003). 
Some cytoplasmic proteins contain highly conserved domains that specifically recognise these 
phosphorylated tyrosines. They are known as SH2 (src homology 2) domains and PTB 
(phosphotyrosine-binding) domains. Cytoplasmic signalling proteins can dock on to the EGFR 
via these domains. Proteins that do not contain SH2 or PTB domains may dock on to the EGFR 
by means of adaptor proteins containing SH2 domains. The cytoplasmic proteins that have 
associated with the activated receptor are themselves activated in different ways, most likely 
either by phosphorylation of a tyrosine residue, by allosteric activation or by translocation to the 
membrane (where they are located in proximity to activating molecules). Further signalling 
proteins contain additional specific domains (such as SH3 domains and pleckstrin homology 
(PH) domains) that recognise certain sequences (such as proline rich sequences and 
phosphoinositide lipids, respectively) in receptor bound proteins and proteins further downstream 
(Schlessinger, 2000). This allows for the extracellular signal to be transduced through the 
intracellular machinery in a way that is specific and not arbitrary.   
 
 
The Ras/MAPK signalling pathway 
 
Several different signaling pathways have the EGFR as a common point of origin. One of them is 
the pathway leading to the activation of the mitogen-activated protein kinases (MAPKs) via Ras. 
In this signalling cascade the adaptor protein Grb2 links up with the EGFR directly via its SH2 
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domain, or indirectly by means of another adaptor protein, Shc, that is tyrosin phosporylated by 
the EGFR and subsequently associates with Grb2. Grb2 contains a SH3 domain by which it is 
constitutively associated with Sos which acts as a GDP-GTP exchange factor. When the Grb2-
Sos complex has docked on to the EGFR it is translocated to the plasma membrane where it 
activates Ras (Schlessinger, 2000). Ras is a family of small membrane bound G-proteins that are 
activated when its GDP is exchanged for GTP. Ras genes are mutated and expressed as an 
overactive variant in about one in four human tumours. Not surprisingly, several pathways with 
point of departure in Ras have been subject to detailed scrutiny (Alberts et al., 2002). 
 
In the Ras/MAPK pathway Ras interacts with a signalling casette of kinases that are highly 
conserved in evolution. At the end of this cascade are the mitogen-activated protein kinases 
(MAPKs). This is a group of enzymes that convey information from cell surface receptors to 
intracellular targets that regulate proliferation, cell death and survival, differentiation and 
migration. Common to these kinases is that they are activated by the phosphorylation of both a 
threonine and a tyrosine residue within each of them (Alberts et al., 2002). The MAPKs are 
activated by the upstream MAPK kinases (MAPKK), which in turn are activated by MAPK 
kinase kinases (MAPKKK), and these again are activated by Ras. Each MAPK is specifically 
activated by only one of the immediate upstream MAPKK. The MAPKKs, however, can be 
activated by a number of different MAPKKKs. This enhances the complexity and diversity of the 
signalling system (Chang and Karin, 2001).  
 
Some of the activated MAPKs are translocated to the nucleus where they regulate transcription 
factors. Others remain in the cytoplasm and regulate gene expression by means of post 
transcriptional mechanisms. As to the biological outcome MAPKs are involved in the regulation 
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of almost all cellular processes, but most well known are their functions as regulators of 
proliferation and cell survival (Chang and Karin, 2001). 
 
 
The role of ERK 
 
The MAPK of particular interest to this study is the extra cellular signal-regulated kinase 1 and 2 
(ERK 1/2). ERK 1/2 is activated specifically by MEK 1/2 (a MAPKK), which in turn is activated 
by Raf-1 (a MAPKKK), and Raf-1 is activated by Ras. When ERK is phosphorylated it 
translocates to the nucleus where it activates the Ets transcription factors. Ets in turn promotes the 
synthesis of c-Fos, which associates with members of the jun family to form AP-1 (activator 
protein 1) (Chang and Karin, 2001).  This dimer binds to the promotor of several genes, the one 
for cyclin D1 being one of them (Cook et al., 1999). Cyclins control the progression through the 
cell cycle and cyclin D1 is active in the G1 phase of the cell cycle. It is part of the cyclin 
dependent protein kinase Cdk4/6 which phosphorylates the Retinoblastoma tumour suppressor 
(Rb), thus releasing the transcription factor E2F and enabling it to induce the synthesis of further 
cyclins (E and A) (Ussar and Voss, 2004; Milde-Langosch 2005). In other words, ERK triggers 
cell cycle progression by promoting the production of certain cyclins at beginning of the cycle. 
Upon stimulation with EGF, ERK also stimulates synthesis of pyrimidine nucleotides, by 
phosphorylating carbamoyl phosphate synthetase II, which is a rate limiting enzyme for this 
process (Wilkinson and Millar, 2000; Chang and Karin, 2001). 
 
ERK is also involved in regulation of cell cycle progression by means of posttranslational 
mechanisms. When ERK activation is sustained, ERK phosphorylates c-Fos and contributes to 
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the stability of this protein (Murphy et al., 2002; Milde-Langosch 2005). Furthermore, the 
construction of cyclinA- and cyclinE-Cdk2 kinase complexes has been linked to the presence of 
the p21 and p27 Cdk inhibitor proteins (CKIs) which function as assembly factors in this context. 
ERK increases the number of CDKs available for this purpose (Wilkinson and Millar, 2000).  
 
However, the role of ERK is not restricted to the beginning of the cell cycle, and neither is the 
nucleus its sole area of operation. Recovery after radiation induced arrest in cell cycle at the 
G2/M check point has been shown to be dependent on ERK (Wilkinson and Millar, 2000). It has 
also been suggested that the natural arrest of unfertilised oocytes at metaphase in meiosis II is 
induced by a cytostatic factor that is in need of ERK for its activity (Chang and Karin, 2001; 
Gross et al., 1999). A part of the pool of activated ERK does not translocate to the nucleus but 
remains in the cytoplasm. ERK in this position takes part in the translation of mRNA into protein 
by phosphorylating the eukaryotic translation factor-4E (eIF-4E) (Wilkinson and Miller, 2000; 
Chang and Karin, 2001).  
 
 
The PI3K pathway 
 
Another important pathway regulating proliferation is the phoshpoinositide 3-OH kinase (PI3K) 
pathway. Like the Ras/MAPK pathway this signalling cascade is activated by RTKs. PI3K may 
be activated by binding directly to the RTK with its regulatory subunit p85, but activation may 
also be dependent on Grb2 and Ras (Cully et al., 2006). The EGFR is one of the RTKs that 
activate PI3K. Activation of the PI3K pathway works in the same direction as the Ras/MAPK 
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pathway by inhibiting apoptosis. It is one of the most important anti-apoptotic pathway in cells, 















How are the numerous signalling molecules organised into separate pathways? The specificity in 
the interaction between signalling proteins is provided for by the fact that they possess specific 
amino acid sequences that recognise corresponding sequences in other proteins, as illustrated in 
the signalling pathway described above. A few other ways of avoiding random combination have 
been described. Certain pathways utilise scaffold proteins in their signal transduction. These are 
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proteins that assemble interacting signalling molecules and isolate them from other closely 
related pathways. Another sorting mechanism is the selective spatial localisation of proteins, such 
as translocation to the membrane or the nucleus (illustrated above), or colocalisation to the 
cytoskeleton (Schlessinger 2000, Chang and Karin, 2001). Specificity also means that the same 
signalling molecule or receptor can have various effects in different sort of cells – and also in 
cells of one and the same kind. This is most likely due to the fact that different cells will have a 
different repertory of effector proteins that interact with the same kind of signalling molecule. 
Cells of the same cell lineage may respond differently to the same extracellular signal because 
they have reached different stages of differentiation. Also the duration and intensity of a signal 
may be decisive for the biologic outcome it is going to have (Wilkinson and Miller, 2000). 
 
 
Attenuation of signal 
 
A number of mechanisms are involved in the negative regulation of signalling in the EGFR 
pathway. Dephosphorylation of activated proteins, downregulation of receptors by endocytosis 
and breakdown of proteins in proteasomes are some of the processes involved, often regulated by 
negative feedback in the pathway. Of particular interest to this study is the deactivation ERK. 
ERK is dephosphorylated by the dual specificity phosphatases MKP1/2 and PAC1, which are 
able to dephosphorylate phosphothreonine and phosphotyrosine in ERK (Hunter, 1995). These 
phosphatases are nuclear proteins that are expressed transiently in response to ERK activation, 
and they act specifically on MAPKs (Alessi, 1995). Removal of one of the phosphates in 
activated ERK is sufficient to deactivate the protein, thus the serine-threonine specific non-
receptor protein phosphatase PP2A is also able to deactivate ERK (Alberts, 2002). PP2A has 
 12
been associated with the inactivation of ERK that takes place within minutes after stimulation 
with growth factor, while the MKPs are associated with the later inactivation that is assumed to 
depend on protein synthesis (Pouysségur and Lenormand, 2003). However, the exact role of each 
of the phosphatases varies among different cell lines and the knowledge about the phosphatases is 





Besides signalling from the EGFR prostaglandins have proved to be another important factor in 
the regulation of cellular proliferation. The link between prostaglandins and cancer has been 
extensively studied, particularly after it was discovered that NSAIDs reduce the risk of colorectal 
cancer. Prostaglandins are derivatives of arachidonic acid, and COX is the enzyme that converts 
arachidonic acid to prostaglandins. The prostaglandin receptors belong to the group of 
heterotrimeric G-protein coupled receptors (GPCRs). One of the best studied prostaglandins is 
prostaglandin E2 (PGE2). This agonist activates different subtypes of prostaglandin receptors, 
and in turn it therefore also activates different G-proteins depending on the subtype of receptor 
that is stimulated. Both Gq, Gs and Gi can participate in PGE2 induced signalling (Bos et al., 
2004). Numerous studies have shown that PGE2 is involved in the promotion of tumour growth 






Cross-talk among different signalling pathways 
 
Traditionally it has been assumed that most signalling pathways operate in separate signalling 
cassettes that have little communication with each other. However, it has become evident that a 
signal can involve several different pathways on its route through the cell. Signals from GPCRs 
and the EGFR have been proved to intermingle, and the cross-talk between these pathways has 
been extensively studied. Another pathway that has been suggested to be involved in mediating 
between GPCR stimulation and ERK activation is signalling via integrin-based focal adhesions. It 
has also been reported that the GPCR itself may act as a scaffold for complex assembly that 
ultimately leads to the activation of ERK (Luttrell et al., 1999). The contribution from each of 
these models varies not only among different sorts of cells but also among cells of the same kind 
(Pierce et al., 2001). 
 
The interaction between these pathways has been studied by means of different kinds of 
experiments. Typically, these experiments have looked for the GPCR ligand-induced activation 
of signalling proteins or receptors at (or below) the point where the two signalling pathways are 
assumed to converge (such as phosphorylation of the EGFR or Shc). In other experiments the 
signalling molecules at (or upstream of) the point of convergence have been inhibited in order to 
see whether the pathway below is affected by this. Instead of using a pharmacological inhibitor 
the same kind of information can be obtained by transfecting cells with a mutated and 
dysfunctional receptor or signalling protein. It can also be demonstrated that proteins from 
different signalling pathways form complexes by showing that they coprecipitate in experiments 
(Luttrell et al., 1999). 
 
 14
Taking a closer look at the pathway below the EGFR it is evident that a signal from a GPCR can 
intervene at several stages in this pathway. The EGFR can be transactivated in a direct or an 
indirect manner. In some cases the signal passes from the GPCR intracellularly (and directly) to 
let a non-receptor tyrosine kinase (such as c-src) activate the EGFR (Eguchi et al., 1998). In other 
cases the signal passes the membrane two more times before the receptor is activated. That is, the 
GPCR may induce the production of EGFR ligands that activate the receptor in an autocrine way, 
or it may cause the release of EGFR ligands that are bound to the surface of the cell as ligand 
precursors (Prenzel et al., 1999). It has also been shown that COX-2 may induce the synthesis of 
EGFRs (Wang and DuBois, 2006). However, as mentioned above, the EGFR need not be 
involved in the cross-talk at all. Integration of the pathways may take place at the level of Ras, or 
even lower, as Ras-independent activation of ERK through GPCR-stimulation has been described 
(Dhanasekharan et al., 1998). 
 
In these models signalling in the EGFR and Ras/MAPK pathways are modulated by signalling 
from GPCR. However, cross-talk may also occur the other way around. Thus, in some cells 
increased expression of COX-2 and PGE2 is a downstream result of stimulation of the EGFR 
(Coffey et al., 1997; Chien et al., 2006; Pai et al., 2006). Hepatocytes are no exception to this. 
Both EGF and TGFα have proved to cause the release of prostaglandins in hepatocytes. 
Prostaglandins, on the other hand, have the ability to amplify the proliferative effect of these 
growth factors (Christoffersen et al., 2000). These models do not necessarily contradict each 




Cross-talk in hepatocytes 
 
PGE2, PGF2α, angiotensin II, vasopressin, glucagon and norepinephrine are all GPCR-agonists 
that reinforce the proliferative effect of EGF in hepatocytes (Refsnes et al., 1994; Christoffersen 
et al., 2000). They are referred to as comitogens because they enhance the effect of mitogens such 
as EGF rather than initiating DNA-synthesis on their own. However, the distinction between 
mitogens and comitogens is not absolute, as some comitogens have proved to be able to induce 
proliferation on their own. The response to comitogenic stimuli in hepatocytes is greatest early in 
the G1 phase of the cell cycle (e.g. 0-10 h after plating), whereas the effect of mitogens is greatest 
when they are added in mid/late G1 (40-50 h). It is assumed that the comitogenic agonists 
accelerate the traverse through the early G1 phase of the cell cycle, thus increasing the pool of 
cells that is responsive to mitogens later in G1. However, the exact mechanism for the 





In the present study we have looked at the mechanisms for the interaction of EGF and PGE2 in 
hepatocytes. In other cells PGE2 has been shown to transphosphorylate the EGFR, and 
downstream events such as DNA-synthesis and activation of ERK have proved to be dependent 
on this transphosphorylation (Pai et al., 2002). In hepatocytes, however, the comitogenic effect of 
a number of GPCR agonist, including the prostaglandin PGF2α has been demonstrated not to be 
dependent on EGFR transphosphorylation (Nilssen et al., 2004). In this study we suggest that in 
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hepatocytes the synergism between GPCR agonists and EGFR is mediated neither by 
transactivation nor by any of the other mechanisms mentioned above. 
 
We have chosen the activation of ERK as one of the “end points” in this study. It is known that 
the proliferative effect of PGE2 is dependent on ERK-activation in certain cells (Pozzi et al., 
2004). The mitogenic effect of EGF in hepatocytes is also dependent on the (sustained) activation 
of ERK (Thoresen et al., 2003). For these reasons it seems adequate to investigate how ERK is 
affected by PGE2 and EGF in hepatocytes. However, it has been shown that comitogenic 
signalling in hepatocytes is not dependent on the activation of ERK in early G1 (when 
hepatocytes are most sensitive to comitogens) (Nilssen et al., 2002). Stimulation of hepatocytes 
with PGF2α and some other GPCR agonists in combination with EGF have shown that ERK may 
well be inhibited in early G1 without curbing the comitogenic effect (Nilssen et al., 2002). PGE2, 
however, is a prostaglandin whose effect on ERK in hepatocytes in not known.  
 
 





MH1C1 cells were from American Type Culture Collection. Dubecco’s modified Eagle’s 
medium, Dulbecco’s phosphate buffered saline, HEPES, penicillin, streptomycin and horse 
serum were from Gibco (Grand Island, NY). William’s medium E was from Whittaker 
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(Walkerville, MD). Collagenase (C-0130), dexamethasone, free bovine serum albumin (BSA) 
(fraction V), collagen (type I from rat tail), actinomycin, natriumorthovanadat and EGF (from 
mouse) were from Sigma Chemical Co. (St. Louis, MO). AG1478 and cycloheximide were from 
Calbiochem (La Jolla, CA). Penstrep was from Cambrex Bio Sciences (Verviers, Belgium). 
Gefitinib was a gift from Astra Zeneca. 
 
 
Cell isolation and culture 
 
Male Wistar rats, 170-230 g, were fed ad libitum. Hepatocytes were isolated by a two-step in 
vitro version (Seglen, 1976) of the collagenase perfusion technique (Berry and Friend, 1969) with 
modifications as previously described (Christofferesen et al., 1984). Hepatocytes as well as 
MH1C1 cells were seeded onto Costar plastic culture wells or flasks, at a cell density of 2 x 
104/cm2. The culture medium used for hepatocytes was a serum-free 1:1 combination of 
William’s medium E and Dulbecco’s modified Eagle’s medium (with final glucose concentration 
8.4 mM). The medium was supplemented with penicillin (67 µg/ml), streptomycin (100 µg/ml) 
insulin (100nM), and dexamethasone (25nM). The culture medium used for MH1C1 was 
Dulbecco’s modified Eagle’s medium. The medium was supplemented with horse serum (10%) 
(apart from the last 24 hours before stimulation), penicillin and streptocmycin (Pen Strep 100 







Aliquots with 20 µg cell protein (total cell lysate prepared in Laemmli buffer) were 
electrophoresed in 12% (w/v) polyacrylamide gels (acrylamide:N’N’-bis-methylene acrylamide 
29:1) followed by immunoblotting with a phospho-specific MAPK antibody detecting p44mapk 
and p42mapk (ERK1 and 2) only when catalytically activated by phosphorylation at Tyr204 or 
Thr202/Tyr204 (New England Biolabs, Inc., Beverly, MA.). Immunoreactive bands were 









Preparatory experiments were done in order to find adequate concentration and treatment time for 
the agonists and inhibitors used in our experiments, and in order to find typical responses of ERK 
in different cells upon stimulation with agonists. Data from some typical experiments with the 
MH1C1 cells are shown in fig. 1. Hepatocytes were investigated by other members of our group. 
Interestingly, the MH1C1 cells proved to be more sensitive to the tyrosine kinase inhibitor 
gefitinib than the hepatocytes, requiring lower doses for complete inhibition of downstream 






Figure 2a Time course for EGF in 
MH1C1 cells. ERK response was 
measured in MH1C1 cells incubated with 
EGF (10 nM) for time periods of 1 min to 
48 h. Phosphorylation of ERK reached a 
maximum after 5 min, thereafter declining 








Figure 2b  Dose-response curve for EGF-induced 
ERK activation in MH1C1 cells. MH1C1 cells were 
stimulated with EGF in various concentrations for 5 
min. The results show that 1 to 10 nM EGF is an 











Figure 2c  ERK response in various cell types to stimulation with EGF (10 nM) and PGE2 (100 µM) for 5 min.  HT-29 and HCT-
116 are human colon cancer cell lines. In HCT-116 cells ERK is constitutively activated. In all other cells ERK is phosphorylated 
upon stimulation with EGF, while only MH1C1 cells show activation of ERK in response to PGE2. Normally ERK would be 












Transphosphorylation of the EGFR is necessary for the PGE2 induced activation of ERK in 
MH1C1 cells, but not in hepatocytes. 
 
As transphosphorylation of the EGFR is assumed to explain cross-talk with GPCRs in many cell 
lines, but not in hepatocytes, we wanted to find out whether transactivation was necessary for the 
PGE2-induced activation of ERK in hepatocytes and MH1C1 cells. Various studies have  
concluded that transactivation is a rapid process (Prenzel et al., 1999), and for this reason the 
cells were incubated with PGE2 or EGF for only 5 minutes. For inhibition of the EGFR we used 
gefitinib and AG1478 which both specifically inhibit the tyrosine kinase of the EGFR. The 
results (fig. 3) show that gefitinib inhibits PGE2 induced activation of ERK in MH1C1 cells, but 
not in hepatocytes. Similar results are shown for AG1478 in hepatocytes. This indicates that 
 
 
Figure 2d  Dose-response curve for getifinib in hepatocytes and MH1C1 cells. The cells were stimulated with EGF for 5 min 
after 3 h in culture, and gefitinib was added 30 min before stimulation with EGF. MH1C1 cells are more sensitive to gefitinib than 
hepatocytes are.  MH1C1 cells are completely inhibited at 3*10-7 M gefitinib, while this concentration has no inhibitory effect in 
hepatocytes, which need 3*10-6 for complete inhibition. 
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MH1C1 cells are dependent on transactivation of the EGFR for the phosphorylation of ERK, 
whereas hepatocytes use other mechanisms for ERK activation. The complete absence of 
phosphorylated ERK in cells treated with EGF and gefitinib or AG1478 confirms that these 




Figure 3  Transphosphorylation of the EGFR is necessary for the PGE2 induced activation of ERK in MH1C1 cells, but not in 
hepatocytes. Hepatocytes and MH1C1 cells were incubated with EGF (10 nM) or PGE2 (100 µM) for 5 min, after 3 h in culture. 





The comitogenic effect of PGE2 in hepatocytes is not dependent on transphosphorylation of 
the EGFR 
 
Knowing that PGE2 enhances EGF induced DNA synthesis we wanted to find out if this 
comitogenic effect is dependent on transactivation of the EGFR. Hepatocytes were stimulated 
with PGE2 in early G1 (at 3 h in culture) and EGF was added in mid/late G1 (at 24 h). AG1478 
was added shortly before PGE2 (at 2,5 h in culture). As the effect of AG1478 is transient it was 
necessary to repeat the treatment with the inhibitor a while after the addition of PGE2 (at 7 h in 
culture). The effect of AG1478 on cells treated with PGE2 alone was examined in an equivalent 
set-up without the addition of EGF. The results (fig. 4.) show that the addition of only PGE2 
slightly increases DNA-synthesis, whereas PGE2 in combination with EGF synergistically 
increases the mitogenic effect of EGF. While AG1478 efficiently inhibits EGF induced DNA 
synthesis it affects neither the small mitogenic nor the comitogenic effect of PGE2. This indicates 














Figure 4  The comitogenic effect of PGE2 in hepatocytes is not dependent on transphosphorylation of the EGFR. a.  EGF (10 nM) was 
added at 24 h and AG1478 (5 µM) at 23,5 and 29 h. The result confirms that inhibition of the EGFR by AG1478 is effective. b. PGE2 
(100 µM) was added at 3 h and AG 1478 (5 µM) was added 2,5 h and 7,5 h. PGE2 has a slight mitogenic effect of its own, and it is not 
inhibited by AG1478. c. Hepatocytes were pretreated with PGE2 (100 µM) at 3 h and AG1478 (5 µM) at 2,5 and 7,5 h. EGF (10 nM) 
was added at 24 h. The comitogenic effect of PGE2 was not inhibited by AG1478. The same experiment was done without PGE2, i.e. 
AG1478 was added at 2,5 and 7,5 h, and EGF was added at 24 h. In this last experiment without PGE2 there is a slight inhibition of the 
mitogenic effect of EGF, due to the fact that the transitory effect of AG1478 is not completely reversed at the time of addition of EGF. All 
cells were harvested at 72 h. Figure a, b and c were borrowed from other members of the group. d. Time table for the addition of PGE2,  




Pretreatment with PGE2 enhances  phosphorylation of ERK in hepatocytes after stimulation 
with EGF 
 
As mentioned above, while ERK is essential to the mitogenic effect of EGF in hepatocytes, the 
comitogenic effect of PGE2 is not dependent on the activation of ERK in early G1. It is 
conceivable, though, that the transmission of the comitogenic signal involves ERK at a later stage 
in the cell cycle. We therefore examined the development of ERK phosphorylation after 
stimulation with EGF in hepatocytes that had been pretreated with PGE2 at an earlier stage. The 
set-up for the experiment was similar to the one illustrated in fig. 4c. PGE2 was added in early 
G1 (at 3 h) and EGF was added in mid-/late G1 (at 24 h). Phosphorylation of ERK was measured 
after 5, 15, 60 and 180 min. The results (fig. 5) show that pretreatment with PGE2 increases 
phosphorylation of ERK. This effect can be traced for as much as three hours after the addition of 
EGF. In other words, as PGE2 both increases EGF induced DNA synthesis and enhances EGF 
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Figure 5  Pretreatment with PGE2 enhances phosphorylation of ERK in hepatocytes after stimulation with EGF. a. Hepatocytes 
were stimulated with PGE2 (100 µM) at 3 h in culture and EGF (10 nM) was added at 24 h. The cells were harvested 1 and 3 h 
after the addition of EGF. The enhancement of ERK phosphorylation is evident after 1 and 3 h. b. The graph shows fold increase 
of phosphorylated ERK in cells pretreated with PGE2 compared to cells treated with EGF only. The figure shows mean +/- SEM of 




Pretreatment with PGE2 imitates the effect of the protein phosphatase inhibitor vanadate on 
ERK phosphorylation in EGF stimulated hepatocytes 
 
The presence of a substance that inhibits the dephosphorylation of phosphorylated ERK could 
produce results that resemble the ones presented in fig. 5. We therefore treated hepatocytes with 
vanadate, which inhibits the phosphatases that dephosphorylate activated ERK, i.e. the dual 
specifity phosphatases MKP1 and PAC1, and the nonreceptor phosphotyrosine phosphatases. 
PGE2 and EGF were added as done in the previous experiment (at 3 and 24 h, respectively), and 
vanadate was added 30 min before EGF. The results (fig. 6) show that pretreatment with PGE2 
imitates the effect of vanadate. In cells stimulated with EGF only the amount of phosphorylated 
ERK declines after an hour. This decline is far less pronounced in cells treated with vanadate, and 
the same effect is seen in cells pretreated with PGE2. There is reason to assume that PGE2 and 
vanadate operate by the same mechanism since there is no additivity in cells that have been 
exposed to both substances in addition to EGF. These results support the suggestion that PGE2 







 Figure 6 Pretreatment with PGE2 
imitates the effect of the protein 
phosphatase inhibitor vanadate in 
EGF stimulated hepatocytes. 
PGE2 (100 µΜ) was added at 3h, 
EGF (10 nM) at 24 h, and 
vanadate at 23,5 h after plating. 
Cells were harvested 5 min and 
60 min after the addition of EGF. 
The figure was borrowed from 
other members of our group. 26
Pretreatment with PGE2 imitates the effect of the protein synthesis inhibitors cycloheximide 
and actinomycin in EGF stimulated hepatocytes 
 
PGE2 can phosphorylate ERK in hepatocytes after only 5 min (fig. 3), but it is evident from the 
results in fig. 5 that PGE2 also has another effect on ERK which takes hours to develop. This 
observation brings to mind the possibility that a more time consuming process such as protein 
synthesis may be involved in the transmission of the comitogenic signal from PGE2. To confirm 
this assumption we treated hepatocytes with inhibitors of protein synthesis. Actinomycin, which 
inhibits transcription, or cycloheximide, which inhibits protein synthesis by interfering with the 
translocation reaction on ribosomes, was added to the cells at 12 h before the cells were 
harvested. PGE2 and EGF were added at 3 h and 24 h respectively. The results (fig. 7) are similar 
to those from the experiment with vanadate: Pretreatment with actinomycin or cycloheximide 
prolongates the phosphorylation of ERK after stimulation with EGF. Pretreatment with PGE2 has 
a similar effect. There is no additivity between PGE2 and the protein synthesis inhibitors when 
the cells are treated with both prostaglandin, growth factor and protein synthesis inhibitor. (The 
only exception to this is found in cells treated with actinomycin at 180 min, where a small 
additive effect of PGE2 and actinomycin can be seen.) These results support the notion that the 
PGE2 may act indirectly, by altering gene transcription and inducing substances that inhibit the 






Figure 7 Pretreatment with PGE2 imitates the effect of the protein synthesis inhibitors cycloheximide and actinomycin in EGF 
stimulated hepatocytes. Hepatocytes were pretreated with PGE2 (100 µM) at 3 h and stimulated with EGF (10 nM) at 24 h in 
culture. ERK was measured 60 and 180 min after the addition of EGF. Cycloheximide (5 µg/ml) or actinomycin (0,2 µg/ml) was 










Figure 8  Prostaglandins modify gene expression in hepatocytes and affect signalling downstream of the EGFR. The figure was 




In the present study we have shown that PGE2 enhances the mitogenic effect of EGF on 
hepatocytes, and we have suggested a mechanism for the cross talk between the pathways 
activated by PGE2 and EGF in hepatocytes. Transactivation, which can explain cross talk in 
many cells lines, including the hepatoma cell line used in this study, is not involved in the 
hepatocytes we have studied. The fact that PGE2 has a long term effect on certain components in 
the EGFR pathway in hepatocytes is compatible with the notion of protein synthesis as a 
mechanism involved in the cross talk. This suggestion is supported by the fact that PGE2 
pretreatment of hepatocytes imitates the effect protein synthesis inhibitors have on ERK 
activation upon stimulation with EGF. Pretreatment with PGE2 also imitates the effect of 
phosphatase inhibitors in an equivalent set-up. We therefore suggest that PGE2 interacts with the 
Ras/MAPK signalling pathway in an indirect way, by modulating gene transcription and inducing 
the synthesis of substances that inhibit the phosphatases that normally dephosphorylate activated 






AP-1    activator protein 1 
c-Fos The term fos was first used for the oncogene encoded by Finkel-Biskis-
Jinkins murine osteogenicsarcoma virus. c-Fos is the normal genetic 
sequence (the proto-oncogene) from which the viral oncogene was derived.
CKI Cdk inhibitor protein 
COX cyclooxygenase 
EGF epidermal growth factor 
EGFR epidermal growth factor receptor 
Erb B receptor tyrosin kinase encoded by retrovirus-associated DNA sequences 
(erbB) originally isolated from, or related to, the avian erythroblastosis 
virus (AEV) 
ERK extracellular-regulated kinase 
Ets E twenty-six domain transcription factors 
GPCR G protein-coupled receptor 
MAPK mitogen-activated protein kinase 
MAPKK mitogen-activated protein kinase kinase 
MAPKKK mitogen-activated protein kinase kinase kinase 
MEK 1/2 MAP/ERK kinase 
MKP1/2 MAPK phosphatase 
PGE2 prostaglandin E2 
PGF2α prostaglandin F2α 
PI3K phosphatidylinositol 3-kinase 
PH domains Pleckstrin homology domain 
PP2A protein phosphatase 2A 
PTB domains phosphotyrosine binding domain 
RTK receptor tyrosine kinase 
SH2/SH3 domains src homology 2/3 domain 
Shc src homology 2 domain-containing protein 
Sos son of sevenless 
src src is the cellular counterpart of v-src, which is the transforming product of 
Rous sarcoma virus.  
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